AR131636A1 - Polipéptidos de dominio fc - variante de il2 recombinantes y politerapia con polipéptidos de unión al antígeno anclados a la membrana - Google Patents
Polipéptidos de dominio fc - variante de il2 recombinantes y politerapia con polipéptidos de unión al antígeno anclados a la membranaInfo
- Publication number
- AR131636A1 AR131636A1 ARP240100115A ARP240100115A AR131636A1 AR 131636 A1 AR131636 A1 AR 131636A1 AR P240100115 A ARP240100115 A AR P240100115A AR P240100115 A ARP240100115 A AR P240100115A AR 131636 A1 AR131636 A1 AR 131636A1
- Authority
- AR
- Argentina
- Prior art keywords
- polypeptide
- recombinant
- mab
- variant
- cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4217—Receptors for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4231—Cytokines
- A61K40/4234—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/11—Antigen recognition domain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/39—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by a specific adjuvant, e.g. cytokines or CpG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se refiere a la politerapia de polipéptidos recombinantes de dominio Fc - variante de IL-2 con polipéptidos de unión al antígeno anclados a la membrana en la prevención o el tratamiento de un cáncer. Reivindicación 1: Un complejo polipeptídico de dominio Fc-variante de IL2 (Fc-IL2v) recombinante en combinación con un polipéptido recombinante de unión al antígeno anclado a la membrana (MAB) o complejo polipeptídico MAB, para su uso en el tratamiento de un cáncer, para su uso en la prevención o el tratamiento de metástasis, o para su uso en la estimulación de una respuesta o función inmunitaria, tal como la actividad de linfocitos T, en el que el complejo polipeptídico Fc-IL2v recombinante comprende: (i) un primer polipéptido que comprende una región CH2-CH3 variante que comprende G329 de acuerdo con la numeración EU, y en el que el primer polipéptido comprende además un polipéptido variante de IL-2 (IL2v) que comprende un polipéptido de IL-2 que comprende las sustituciones aminoacídicas F42A, Y45A y L72G en las que la numeración es con relación a la secuencia de IL-2 humana SEQ ID Nº 40; y (ii) un segundo polipéptido que comprende una región CH2-CH3 variante que comprende G329 de acuerdo con la numeración EU, en el que el complejo polipeptídico Fc-IL2v recombinante no comprende un resto de unión al antígeno, y en el que el polipéptido MAB o complejo polipeptídico MAB comprende un resto de unión al antígeno, o un componente del mismo, y un dominio transmembrana, en el que el resto de unión al antígeno se une a una región CH2-CH3 variante que comprende la sustitución aminoacídica P329G de acuerdo con la numeración EU con relación a la secuencia de aminoácidos de una región CH2-CH3 de referencia que comprende P329 de acuerdo con la numeración EU, a la que no se une el resto de unión al antígeno. Reivindicación 2: Un complejo polipeptídico de dominio Fc-variante de IL2 (Fc-IL2v) recombinante, que comprende: (i) un primer polipéptido que comprende una región CH2-CH3 variante que comprende G329 de acuerdo con la numeración EU, y en el que el primer polipéptido comprende además un polipéptido variante de IL-2 (IL2v) que comprende un polipéptido de IL-2 que comprende las sustituciones aminoacídicas F42A, Y45A y L72G en las que la numeración es con relación a la secuencia de IL-2 humana SEQ ID Nº 40; y (ii) un segundo polipéptido que comprende una región CH2-CH3 variante que comprende G329 de acuerdo con la numeración EU, en el que el complejo polipeptídico Fc-IL2v recombinante no comprende un resto de unión al antígeno. Reivindicación 17: Una célula que comprende un polipéptido MAB o complejo polipeptídico MAB recombinante de acuerdo con una cualquiera de las reivindicaciones 1 u 11 a 16. Reivindicación 18: Un procedimiento de producción de un grupo enriquecido de células que comprende poner en contacto un grupo inicial de células que comprende al menos una célula de acuerdo con la reivindicación 17 con el complejo polipeptídico Fc-IL2v recombinante de una cualquiera de las reivindicaciones 2 o 6 a 10 e incubar las células hasta que la fracción de células que comprende el polipéptido MAB o complejo polipeptídico MAB recombinante alcance una fracción deseada del grupo total de células para producir el grupo enriquecido de células. Reivindicación 19: Un ácido nucleico, o una pluralidad de ácidos nucleicos, que codifican un complejo polipeptídico de dominio Fc-variante de IL2 (Fc-IL2v) recombinante de acuerdo con una cualquiera de las reivindicaciones 2 o 6 a 10, o un polipéptido MAB o complejo polipeptídico MAB recombinante de acuerdo con una cualquiera de las reivindicaciones 1 u 11 a 16. Reivindicación 20: Un vector de expresión, o una pluralidad de vectores de expresión, que comprenden un ácido nucleico de acuerdo con la reivindicación 19. Reivindicación 21: Una célula que comprende un polipéptido MAB o complejo polipeptídico MAB recombinante de acuerdo con una cualquiera de las reivindicaciones 1 u 11 a 16, un ácido nucleico o una pluralidad de ácidos nucleicos de acuerdo con la reivindicación 19, o un vector de expresión o una pluralidad de vectores de expresión de acuerdo con la reivindicación 20. Reivindicación 25: Un procedimiento de producción de un grupo enriquecido de células que comprende poner en contacto un grupo inicial de células que comprende al menos una célula de acuerdo con la reivindicación 21 con el complejo polipeptídico Fc-IL2v recombinante de una cualquiera de las reivindicaciones 2 o 6 a 10 e incubar las células hasta que la fracción de células que comprende el polipéptido MAB o complejo polipeptídico MAB recombinante alcance una fracción deseada del grupo total de células para producir el grupo enriquecido de células. Reivindicación 26: Una composición farmacéutica que comprende un complejo polipeptídico de dominio Fc-variante de IL2 (Fc-IL2v) recombinante de acuerdo con una cualquiera de las reivindicaciones 2 o 6 a 10, una célula de acuerdo con la reivindicación 21 o un grupo enriquecido de células producido de acuerdo con la reivindicación 25.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23152578 | 2023-01-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR131636A1 true AR131636A1 (es) | 2025-04-16 |
Family
ID=85132942
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240100114A AR131635A1 (es) | 2023-01-20 | 2024-01-18 | Inmunoconjugados |
| ARP240100115A AR131636A1 (es) | 2023-01-20 | 2024-01-18 | Polipéptidos de dominio fc - variante de il2 recombinantes y politerapia con polipéptidos de unión al antígeno anclados a la membrana |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240100114A AR131635A1 (es) | 2023-01-20 | 2024-01-18 | Inmunoconjugados |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20260083855A1 (es) |
| EP (2) | EP4651885A1 (es) |
| JP (2) | JP2026504860A (es) |
| KR (1) | KR20250135861A (es) |
| CN (2) | CN120548192A (es) |
| AR (2) | AR131635A1 (es) |
| AU (1) | AU2024209384A1 (es) |
| CL (1) | CL2025002122A1 (es) |
| CO (1) | CO2025009694A2 (es) |
| CR (1) | CR20250288A (es) |
| IL (1) | IL321769A (es) |
| MX (1) | MX2025008323A (es) |
| PE (1) | PE20252169A1 (es) |
| TW (1) | TW202444751A (es) |
| WO (2) | WO2024153722A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026052652A1 (en) * | 2024-09-03 | 2026-03-12 | F. Hoffmann-La Roche Ag | Cytokine receptor agonist |
| WO2026052654A1 (en) * | 2024-09-03 | 2026-03-12 | F. Hoffmann-La Roche Ag | Cytokine receptor agonist |
| WO2026104330A1 (en) * | 2024-11-12 | 2026-05-21 | F. Hoffmann-La Roche Ag | Pd-1-regulated il-2 immunoconjugates and uses thereof |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2808353C2 (de) | 1977-04-18 | 1984-01-19 | Hitachi Metals, Ltd., Tokyo | Ohrring |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
| EP0229108B1 (en) | 1985-06-26 | 1990-12-27 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| JP2003516755A (ja) | 1999-12-15 | 2003-05-20 | ジェネンテック・インコーポレーテッド | ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法 |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| CA2456470A1 (en) | 2001-08-13 | 2003-02-27 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
| EP1454138B1 (en) | 2001-12-04 | 2012-01-18 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
| US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
| EP1513879B1 (en) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
| AU2004205631A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| BRPI0607315B1 (pt) | 2005-02-07 | 2022-05-17 | Roche Glycart Ag | Molécula de ligação ao antígeno anti-egfr humanizada e seus usos, composição farmacêutica, e método para detectar a presença de egfr em uma amostra |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| EP2016101A2 (en) | 2006-05-09 | 2009-01-21 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| PT2066796E (pt) | 2006-09-20 | 2011-10-11 | Mt Biomethan Gmbh | Procedimento e dispositivo para a separação do metano e do dióxido de carbono do biogás |
| WO2009061853A2 (en) | 2007-11-05 | 2009-05-14 | Massachusetts Institute Of Technology | Mutant interleukin-2 (il-2) polypeptides |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| RU2583876C2 (ru) | 2009-08-17 | 2016-05-10 | Роше Гликарт Аг | Иммуноконъюгаты направленного действия |
| US20130089554A1 (en) | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| CN105440123B (zh) | 2011-02-10 | 2020-10-09 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
| LT2691417T (lt) | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antikūno fc variantai |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| US9527927B2 (en) | 2011-12-20 | 2016-12-27 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
| KR102069397B1 (ko) | 2012-02-15 | 2020-01-22 | 에프. 호프만-라 로슈 아게 | Fc-수용체 기재 친화성 크로마토그래피 |
| WO2013157953A1 (en) | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
| SI3356404T1 (sl) | 2015-10-02 | 2021-11-30 | F. Hoffmann-La Roche Ag | Protitelesa proti PD1 in postopki uporabe |
| CA3056837A1 (en) | 2017-03-27 | 2018-10-04 | F. Hoffmann-La Roche Ag | Improved antigen binding receptors |
| KR102461885B1 (ko) | 2017-04-03 | 2022-11-03 | 에프. 호프만-라 로슈 아게 | 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체 |
| JP7765181B2 (ja) * | 2017-12-19 | 2025-11-06 | ゼンコア インコーポレイテッド | 改変されたil-2 fc融合タンパク質 |
| TWI815194B (zh) * | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| CA3203977A1 (en) * | 2020-12-04 | 2022-06-09 | Visterra, Inc. | Methods of using interleukin-2 agents |
-
2024
- 2024-01-18 WO PCT/EP2024/051089 patent/WO2024153722A1/en not_active Ceased
- 2024-01-18 CN CN202480008190.3A patent/CN120548192A/zh active Pending
- 2024-01-18 KR KR1020257027374A patent/KR20250135861A/ko active Pending
- 2024-01-18 AR ARP240100114A patent/AR131635A1/es unknown
- 2024-01-18 WO PCT/EP2024/051096 patent/WO2024153725A1/en not_active Ceased
- 2024-01-18 AR ARP240100115A patent/AR131636A1/es unknown
- 2024-01-18 JP JP2025540985A patent/JP2026504860A/ja active Pending
- 2024-01-18 CN CN202480008189.0A patent/CN120676957A/zh active Pending
- 2024-01-18 EP EP24702052.2A patent/EP4651885A1/en active Pending
- 2024-01-18 AU AU2024209384A patent/AU2024209384A1/en active Pending
- 2024-01-18 TW TW113102022A patent/TW202444751A/zh unknown
- 2024-01-18 CR CR20250288A patent/CR20250288A/es unknown
- 2024-01-18 EP EP24702251.0A patent/EP4651886A1/en not_active Withdrawn
- 2024-01-18 PE PE2025001495A patent/PE20252169A1/es unknown
- 2024-01-18 JP JP2025541707A patent/JP2026506471A/ja active Pending
-
2025
- 2025-06-25 IL IL321769A patent/IL321769A/en unknown
- 2025-07-11 US US19/267,102 patent/US20260083855A1/en active Pending
- 2025-07-17 MX MX2025008323A patent/MX2025008323A/es unknown
- 2025-07-17 CO CONC2025/0009694A patent/CO2025009694A2/es unknown
- 2025-07-17 US US19/272,092 patent/US20260091062A1/en active Pending
- 2025-07-18 CL CL2025002122A patent/CL2025002122A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4651885A1 (en) | 2025-11-26 |
| TW202444751A (zh) | 2024-11-16 |
| JP2026506471A (ja) | 2026-02-25 |
| WO2024153722A1 (en) | 2024-07-25 |
| CN120676957A (zh) | 2025-09-19 |
| MX2025008323A (es) | 2025-08-01 |
| KR20250135861A (ko) | 2025-09-15 |
| CN120548192A (zh) | 2025-08-26 |
| CL2025002122A1 (es) | 2025-08-22 |
| US20260091062A1 (en) | 2026-04-02 |
| AR131635A1 (es) | 2025-04-16 |
| AU2024209384A1 (en) | 2025-06-26 |
| PE20252169A1 (es) | 2025-09-04 |
| WO2024153725A1 (en) | 2024-07-25 |
| JP2026504860A (ja) | 2026-02-10 |
| CO2025009694A2 (es) | 2025-08-08 |
| US20260083855A1 (en) | 2026-03-26 |
| IL321769A (en) | 2025-08-01 |
| EP4651886A1 (en) | 2025-11-26 |
| CR20250288A (es) | 2025-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11229694B2 (en) | Vaccine against RSV | |
| JP2021191265A5 (es) | ||
| AR126987A2 (es) | Inmunoconjugados | |
| MX2024015050A (es) | L-asparaginasa modificada | |
| DE3880739D1 (de) | Expression von menschlichem proapolipoprotein a-1. | |
| PE20252169A1 (es) | Polipeptidos de dominio fc - variante de il2 recombinantes y politerapia con polipeptidos de union al antigeno anclados a la membrana | |
| PE64396A1 (es) | Proteina accesoria del receptor de la interleucina 1 | |
| AR123788A1 (es) | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas | |
| AR125007A1 (es) | Fusiones heterodiméricas de relaxina y usos de las mismas | |
| AR123187A1 (es) | Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer | |
| AR128627A1 (es) | Agente terapéutico para enfermedades neurodegenerativas | |
| BR112022011975A2 (pt) | Polipeptídeo de interferon-¿2 modificado, polipeptídeo gmop-interferon-¿2 modificado, ácido nucleico, plasmídeo, vetor, linha de célula, método para purificação do polipeptídeo de interferon-¿2 modificado, composição farmacêutica, método para uso de um ou mais dos polipeptídeos de interferon-¿2 modificados e método para tratar uma condição médica em um indivíduo | |
| AR126846A1 (es) | Genes del factor viii optimizados | |
| PE20230826A1 (es) | Peptidos y combinaciones de peptidos para uso en inmunoterapia contra la infeccion por sars-cov-2 | |
| Negro et al. | Synthesis, purification, and characterization of human ciliary neuronotrophic factor from E. coli | |
| Franciskovich et al. | A systematic evaluation of the inhibition of HIV-1 protease by its C-and N-terminal peptides | |
| AR134771A1 (es) | PROTEÍNAS DE FUSIÓN QUE COMPRENDEN ENZIMAS a-GLUCOSIDASAS ÁCIDAS Y MÉTODOS DE ESTAS | |
| ES2251483T3 (es) | Molecula de acido nucleico que comprende una secuencia de acido nucleico que codifica una quimiocina sdf-1 gamma, un precursor neuropeptidico o al menos un neuropeptido. | |
| BR112022022615A2 (pt) | Proteína nova e usos terapêuticos e cosméticos da mesma | |
| AR126388A1 (es) | Peptidos lineales que inhiben la fosforilacion mediada por ck2 y composiciones que los comprenden | |
| Sherman et al. | Sequence analysis of an immunogenic and neutralizing domain of the human T-cell lymphoma/leukemia virus type I gp46 surface membrane protein among various primate T-cell lymphoma/leukemia virus isolates including those from a patient with both HTLV-I-associated myelopathy and adult T-cell leukemia | |
| AR114927A1 (es) | Neoantígenos y usos de los mismos | |
| MX2022003002A (es) | Secuencia de extension n-terminal para la expresion de peptidos terapeuticos recombinantes. | |
| CN105504070A (zh) | 一种四分支多肽及其应用 | |
| RU2021100733A (ru) | Неоантигены и их применение |